Cavernous angioma future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
Line 33: Line 33:


*Evolving techniques in identifying the [[iron content]] and [[permeability]] of [[vessels]]:  
*Evolving techniques in identifying the [[iron content]] and [[permeability]] of [[vessels]]:  
**Quantitative susceptibility mapping (QSM) <ref name="pmid27494817">{{cite journal| author=Girard R, Fam MD, Zeineddine HA, Tan H, Mikati AG, Shi C | display-authors=etal| title=Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. | journal=J Neurosurg | year= 2017 | volume= 127 | issue= 1 | pages= 102-110 | pmid=27494817 | doi=10.3171/2016.5.JNS16687 | pmc=6421857 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27494817  }} </ref><ref name="pmid25966944">{{cite journal| author=Mikati AG, Khanna O, Zhang L, Girard R, Shenkar R, Guo X | display-authors=etal| title=Vascular permeability in cerebral cavernous malformations. | journal=J Cereb Blood Flow Metab | year= 2015 | volume= 35 | issue= 10 | pages= 1632-9 | pmid=25966944 | doi=10.1038/jcbfm.2015.98 | pmc=4640319 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25966944  }} </ref><ref name="pmid24302484">{{cite journal| author=Mikati AG, Tan H, Shenkar R, Li L, Zhang L, Guo X | display-authors=etal| title=Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations. | journal=Stroke | year= 2014 | volume= 45 | issue= 2 | pages= 598-601 | pmid=24302484 | doi=10.1161/STROKEAHA.113.003548 | pmc=4351041 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24302484  }} </ref><ref name="pmid24323376">{{cite journal| author=Hart BL, Taheri S, Rosenberg GA, Morrison LA| title=Dynamic contrast-enhanced MRI evaluation of cerebral cavernous malformations. | journal=Transl Stroke Res | year= 2013 | volume= 4 | issue= 5 | pages= 500-6 | pmid=24323376 | doi=10.1007/s12975-013-0285-y | pmc=3939060 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24323376  }} </ref>
**[[Quantitative susceptibility mapping]] (QSM) <ref name="pmid27494817">{{cite journal| author=Girard R, Fam MD, Zeineddine HA, Tan H, Mikati AG, Shi C | display-authors=etal| title=Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. | journal=J Neurosurg | year= 2017 | volume= 127 | issue= 1 | pages= 102-110 | pmid=27494817 | doi=10.3171/2016.5.JNS16687 | pmc=6421857 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27494817  }} </ref><ref name="pmid25966944">{{cite journal| author=Mikati AG, Khanna O, Zhang L, Girard R, Shenkar R, Guo X | display-authors=etal| title=Vascular permeability in cerebral cavernous malformations. | journal=J Cereb Blood Flow Metab | year= 2015 | volume= 35 | issue= 10 | pages= 1632-9 | pmid=25966944 | doi=10.1038/jcbfm.2015.98 | pmc=4640319 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25966944  }} </ref><ref name="pmid24302484">{{cite journal| author=Mikati AG, Tan H, Shenkar R, Li L, Zhang L, Guo X | display-authors=etal| title=Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations. | journal=Stroke | year= 2014 | volume= 45 | issue= 2 | pages= 598-601 | pmid=24302484 | doi=10.1161/STROKEAHA.113.003548 | pmc=4351041 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24302484  }} </ref><ref name="pmid24323376">{{cite journal| author=Hart BL, Taheri S, Rosenberg GA, Morrison LA| title=Dynamic contrast-enhanced MRI evaluation of cerebral cavernous malformations. | journal=Transl Stroke Res | year= 2013 | volume= 4 | issue= 5 | pages= 500-6 | pmid=24323376 | doi=10.1007/s12975-013-0285-y | pmc=3939060 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24323376  }} </ref>
**Dynamic contrast-enhanced quantitative [[perfusion]]
**[[Dynamic contrast-enhanced quantitative perfusion]]


*[[Serum biomarkers]] reflect [[angiogenesis]], and [[inflammatory]] activity: <ref name="pmid29720384">{{cite journal| author=Girard R, Zeineddine HA, Koskimäki J, Fam MD, Cao Y, Shi C | display-authors=etal| title=Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. | journal=Circ Res | year= 2018 | volume= 122 | issue= 12 | pages= 1716-1721 | pmid=29720384 | doi=10.1161/CIRCRESAHA.118.312680 | pmc=5993629 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29720384  }} </ref>
*[[Serum biomarkers]] reflect [[angiogenesis]], and [[inflammatory]] activity: <ref name="pmid29720384">{{cite journal| author=Girard R, Zeineddine HA, Koskimäki J, Fam MD, Cao Y, Shi C | display-authors=etal| title=Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. | journal=Circ Res | year= 2018 | volume= 122 | issue= 12 | pages= 1716-1721 | pmid=29720384 | doi=10.1161/CIRCRESAHA.118.312680 | pmc=5993629 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29720384  }} </ref>

Latest revision as of 12:12, 11 March 2022

Cavernous angioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Cavernous angioma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

CT

MRI

MRA

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cavernous angioma future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cavernous angioma future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cavernous angioma future or investigational therapies

CDC on Cavernous angioma future or investigational therapies

Cavernous angioma future or investigational therapies in the news

Blogs on Cavernous angioma future or investigational therapies

Directions to Hospitals Treating Cavernous angioma

Risk calculators and risk factors for Cavernous angioma future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorrraine F. Co, D.M.D., M.D.

Future Investigations

Insights

Possible Medications that can Reduce Risk of Bleeding

Advances in Biomarkers

References

  1. ↑ Fischer A, Zalvide J, Faurobert E, Albiges-Rizo C, Tournier-Lasserve E (2013). "Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis". Trends Mol Med. 19 (5): 302–8. doi:10.1016/j.molmed.2013.02.004. PMID 23506982.
  2. ↑ 2.0 2.1 Retta SF, Glading AJ (2016). "Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin". Int J Biochem Cell Biol. 81 (Pt B): 254–270. doi:10.1016/j.biocel.2016.09.011. PMC 5155701. PMID 27639680.
  3. ↑ 3.0 3.1 Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N; et al. (2017). "Endothelial TLR4 and the microbiome drive cerebral cavernous malformations". Nature. 545 (7654): 305–310. doi:10.1038/nature22075. PMC 5757866. PMID 28489816.
  4. ↑ Zafar A, Quadri SA, Farooqui M, Ikram A, Robinson M, Hart BL; et al. (2019). "Familial Cerebral Cavernous Malformations". Stroke. 50 (5): 1294–1301. doi:10.1161/STROKEAHA.118.022314. PMC 6924279 Check |pmc= value (help). PMID 30909834.
  5. ↑ Witiw CD, Abou-Hamden A, Kulkarni AV, Silvaggio JA, Schneider C, Wallace MC (2012). "Cerebral cavernous malformations and pregnancy: hemorrhage risk and influence on obstetrical management". Neurosurgery. 71 (3): 626–30, discussion 631. doi:10.1227/NEU.0b013e31825fd0dc. PMID 22710379.
  6. ↑ Chohan MO, Marchiò S, Morrison LA, Sidman RL, Cavenee WK, Dejana E; et al. (2019). "Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review". JAMA Neurol. 76 (4): 492–500. doi:10.1001/jamaneurol.2018.3634. PMID 30476961.
  7. ↑ 7.0 7.1 7.2 Gibson CC, Zhu W, Davis CT, Bowman-Kirigin JA, Chan AC, Ling J; et al. (2015). "Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation". Circulation. 131 (3): 289–99. doi:10.1161/CIRCULATIONAHA.114.010403. PMC 4356181. PMID 25486933.
  8. ↑ De Luca E, Pedone D, Moglianetti M, Pulcini D, Perrelli A, Retta SF; et al. (2018). "Multifunctional Platinum@BSA-Rapamycin Nanocarriers for the Combinatorial Therapy of Cerebral Cavernous Malformation". ACS Omega. 3 (11): 15389–15398. doi:10.1021/acsomega.8b01653. PMC 6288776. PMID 30556006.
  9. ↑ Wüstehube J, Bartol A, Liebler SS, Brütsch R, Zhu Y, Felbor U; et al. (2010). "Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling". Proc Natl Acad Sci U S A. 107 (28): 12640–5. doi:10.1073/pnas.1000132107. PMC 2906569. PMID 20616044.
  10. ↑ Bravi L, Rudini N, Cuttano R, Giampietro C, Maddaluno L, Ferrarini L; et al. (2015). "Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice". Proc Natl Acad Sci U S A. 112 (27): 8421–6. doi:10.1073/pnas.1501352112. PMC 4500248. PMID 26109568.
  11. ↑ McDonald DA, Shi C, Shenkar R, Stockton RA, Liu F, Ginsberg MH; et al. (2012). "Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease". Stroke. 43 (2): 571–4. doi:10.1161/STROKEAHA.111.625467. PMC 3265629. PMID 22034008.
  12. ↑ Shenkar R, Shi C, Austin C, Moore T, Lightle R, Cao Y; et al. (2017). "RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations". Stroke. 48 (1): 187–194. doi:10.1161/STROKEAHA.116.015013. PMC 5183488. PMID 27879448.
  13. ↑ 13.0 13.1 Weiner GM, Ducruet AF (2017). "Fasudil Slows Development of Cavernous Malformations". Neurosurgery. 80 (5): N25–N27. doi:10.1093/neuros/nyx100. PMID 28586486.
  14. ↑ 14.0 14.1 Apra C, Dumot C, Bourdillon P, Pelissou-Guyotat I (2019). "Could propranolol be beneficial in adult cerebral cavernous malformations?". Neurosurg Rev. 42 (2): 403–408. doi:10.1007/s10143-018-01074-0. PMID 30610500.
  15. ↑ 15.0 15.1 Berti I, Marchetti F, Skabar A, Zennaro F, Zanon D, Ventura A (2014). "Propranolol for cerebral cavernous angiomatosis: a magic bullet". Clin Pediatr (Phila). 53 (2): 189–90. doi:10.1177/0009922813492885. PMID 23804539.
  16. ↑ 16.0 16.1 Reinhard M, Schuchardt F, Meckel S, Heinz J, Felbor U, Sure U; et al. (2016). "Propranolol stops progressive multiple cerebral cavernoma in an adult patient". J Neurol Sci. 367: 15–7. doi:10.1016/j.jns.2016.04.053. PMID 27423555.
  17. ↑ 17.0 17.1 Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID 2017.12.JNS172404. https://doi.org/10.3171/ 2017.12.JNS172404. Check |pmid= value (help).
  18. ↑ 18.0 18.1 Zabramski JM, Kalani MYS, Filippidis AS, Spetzler RF (2016). "Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage". World Neurosurg. 88: 631–639. doi:10.1016/j.wneu.2015.11.003. PMID 26578351.
  19. ↑ Girard R, Fam MD, Zeineddine HA, Tan H, Mikati AG, Shi C; et al. (2017). "Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations". J Neurosurg. 127 (1): 102–110. doi:10.3171/2016.5.JNS16687. PMC 6421857. PMID 27494817.
  20. ↑ Mikati AG, Khanna O, Zhang L, Girard R, Shenkar R, Guo X; et al. (2015). "Vascular permeability in cerebral cavernous malformations". J Cereb Blood Flow Metab. 35 (10): 1632–9. doi:10.1038/jcbfm.2015.98. PMC 4640319. PMID 25966944.
  21. ↑ Mikati AG, Tan H, Shenkar R, Li L, Zhang L, Guo X; et al. (2014). "Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations". Stroke. 45 (2): 598–601. doi:10.1161/STROKEAHA.113.003548. PMC 4351041. PMID 24302484.
  22. ↑ Hart BL, Taheri S, Rosenberg GA, Morrison LA (2013). "Dynamic contrast-enhanced MRI evaluation of cerebral cavernous malformations". Transl Stroke Res. 4 (5): 500–6. doi:10.1007/s12975-013-0285-y. PMC 3939060. PMID 24323376.
  23. ↑ Girard R, Zeineddine HA, Koskimäki J, Fam MD, Cao Y, Shi C; et al. (2018). "Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth". Circ Res. 122 (12): 1716–1721. doi:10.1161/CIRCRESAHA.118.312680. PMC 5993629. PMID 29720384.
Retrieved from "https://www.wikidoc.org/index.php?title=Cavernous_angioma_future_or_investigational_therapies&oldid=1720875"